US court finds Copaxone patent invalid again: Natco Pharma

Last Updated: Friday, June 19, 2015, 15:34

The Natco stock was trading at Rs 2,187.05, up 5.33 percent, on BSE at 1513 hours.

Natco Pharma mulls hiking FII limit, looks to raise funds

Last Updated: Tuesday, May 12, 2015, 13:48

Natco Pharma plans to increase the limit of foreign institutional investors (FIIs) to 49 percent as it looks to raise more funds through issuing shares or convertible securities.

The Compulsions and Repercussions of Compulsory Licensing

Last Updated: Friday, October 12, 2012, 17:39

The recent erosion of investor confidence in India that is doing the rounds in corporate circles is due to a variety of self-defeating strategies that have been adopted by the government.

The Compulsions and Repercussions of Compulsory Licensing

Last Updated: Sunday, September 2, 2012, 17:23

The recent erosion of investor confidence in India that is doing the rounds in corporate circles is due to a variety of self-defeating strategies that have been adopted by the government.

Natco Pharma Q1 net up 21.66% at Rs 17 cr

Last Updated: Saturday, August 11, 2012, 21:00

The company had posted a net profit of Rs 14.03 crore for the corresponding quarter previous fiscal, Natco Pharma said in a filing to BSE.

Bayer challenges Nexavar generic licence order

Last Updated: Monday, May 7, 2012, 19:56

Drugmaker Bayer has filed an appeal against an Indian Patents Office's order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German firm's cancer drug 'Nexavar' in India, with the Intellectual Property Appellate Board.

Govt lets sale of cancer drug cheaper by 30 times

Last Updated: Wednesday, March 14, 2012, 00:27

In a first, India on Tuesday invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.

Govt lets sale of cancer drug cheaper by 30 times

Last Updated: Tuesday, March 13, 2012, 09:07

In a first, India on Tuesday invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price, over 30 times lower than charged by its patent-holder Bayer Corporation.

Sun Pharma's Dilip Shanghvi buys 3.5% stake in Natco Pharma

Last Updated: Thursday, December 8, 2011, 19:47

Sun Pharma's chief Dilip S Shanghvi has bought 10 lakh shares or about 3.5 percent stake in the drugmaker's smaller rival Natco Pharma for an estimated Rs 25 crore.